In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Selected Start-Ups (7/00)

Executive Summary

In Vivo summarizes the technologies of several recently founded companies: formed through the combination of Scriptgen Pharmaceuticals Inc. and key scientists and related assets of the EMBL, Scripps and UCSD, Anadys Pharmaceuticals Inc. will discover and develop new drugs to treat infectious diseases, including those that are resistant to current therapies. Astex Technology Ltd. will offer high throughput X-ray crystallography to provide rapid generation of protein crystal structures. Biosupplies.com has launched the first Internet marketplace for custom-built DNA oligonucleotides and peptides with technology that allows researchers to design products to their own specifications and then shop for them online. Friz Biochem GmbH was founded in August 1999 to develop a DNA biochip platform for the rapid detection of genetic information. Minerva Pharmaceuticals Inc. will develop diagnostic and therapeutic products that will allow human cancers to be diagnosed and treated at an early stage, before they become life threatening. Founded in November 1999, Motac Neuroscience Ltd. will offer technical expertise and state-of-the art facilities to support the drug discovery efforts of its strategic partners.

You may also be interested in...



Zydus Cadila Readies Injectables Push Amid Tepid US Growth Outlook

Zydus Cadila expects domestic sales to improve and the US generics business to grow in “mid to high” single digits during FY21 after both saw a coronavirus-related hit in Q1. Meanwhile, approvals for a few biologics are expected, its COVID-19 vaccine candidate has just entered Phase II studies and remdesivir launch looms.

Revlon In COVID-19 Tailspin; E-Commerce, At-Home Beauty Provide Lifts

At-home nail and hair care and e-commerce were bright spots in a numbing second quarter for Revlon, which was hit hard by mass retail and salon channel closures at a time of ongoing transformation.

US FDA, Sponsors Eye Best Practices For Virtual AdComms

Agency has created a centralized team to help review divisions with virtual advisory committee preparations and is trying to notify sponsors earlier in the review process about the need for a panel; sponsors cite importance of having a back channel of communications so team members can communicate with each other while an AdComm is underway.

Related Companies

UsernamePublicRestriction

Register

LL1132992

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel